Recurrent Pericarditis Market Analysis

The Global Recurrent Pericarditis Market is estimated to be valued at USD 555.1 billion in 2024 and is expected to reach USD 810.3 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031. Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are widely used as the first line of treatment for recurrent pericarditis, driving the market growth.

The market is expected to witness positive growth over the forecast period owing to rising incidences of recurrent pericarditis disorders and increasing sales of corticosteroids and NSAIDs, advancements in targeted therapies and increasing awareness. Traditional treatments, such as NSAIDs and colchicine, often fail in resistant cases, prompting a shift toward biologic therapies like IL-1 inhibitors, including rilonacept and anakinra. The RHAPSODY trial in 2023 highlighted rilonacept's efficacy in significantly reducing recurrence rates, marking a paradigm shift in management strategies. The market evolution is supported by ongoing research and clinical trials focusing on innovative approaches to reduce disease burden and improve patient outcomes, making targeted treatment a key focus area. The growing awareness regarding recurrent pericarditis conditions and availability of different treatment options are expected to provide opportunities for the recurrent pericarditis market between 2024 and 2031.